hrp0086p2-p708 | Endocrinology and Multisystemic Diseases P2 | ESPE2016

Inhibition of NAMPT Increases the Sensitivity of Leukemia Cells for Etoposide

Gorski Theresa , Petzold-Quinque Stefanie , Richter Sandy , Schuster Susanne , Penke Melanie , Kiess Wieland , Garten Antje

Background: Cancer cells have a high NAD turnover rate due to their increased cell proliferation and DNA repair. Nicotinamide phosphoribosyltransferase (NAMPT) is the key enzyme of the NAD salvage pathway, a regulator of the intracellular NAD pool and of the activity of Sirtuins (SIRTs), a class of NAD-dependent deacetylases.Objective and hypotheses: Cancer cells are highly dependent on NAD and are expected to be more susceptible to an inhibition of NAD ...

hrp0084p2-453 | Growth | ESPE2015

Cross-Sectional and Longitudinal Follow-Up of Changes in Glucose Metabolism in Prepubertal GH-Treated SGA-Patients: Results of an Unicentric Study

Sydlik Carmen , Bechtold Susanne , Weissenbacher Claudia , Roeb Julia , Buckl Matthias , Putzker Stefanie , Schmidt Heinrich

Background: Several studies show impaired glucose tolerance at a certain number of years after start of growth hormone in SGA-children.Objective and hypotheses: To perform a longitudinal and cross-sectional evaluation of the oGTTs (glucose-insulin-pairs) in prepubertal GH-treated SGA-children and to evaluate if ISI and HOMA are effective surrogates for glucose tolerance and of prognostic value (0–1 year data).Method: In 81 pre...

hrp0084p3-972 | GH & IGF | ESPE2015

Time Trends in Baseline Characteristics (2006–2014) in Short Children with Growth Hormone Deficiency (GHD), Born Small for Gestational Age (SGA) and with Ullrich-Turner Syndrome (TS) Enrolled in Nordinet® International Outcomes Study (IOS) in Germany and Czech Republic

Dorr Helmuth Gunther , Bramswig Jurgen , Meckes-Ferber Stefanie , Pournara Effie , Pedersen Birgitte Tonnes , Snajderova Marta

Background: Early diagnosis of growth disorders and initiation of GH therapy at a younger age improves clinical outcomes.Aims and objectives: To analyse time trends in baseline parameters at GH treatment start (2006 – 2014) in short children with GHD, SGA and TS from Germany and Czech Republic enrolled in NordiNet® IOS (NCT00960128).Method: Baseline data (chronological age, height, weight, BMI, GH dose) from pa...

hrp0094p2-195 | Fat, metabolism and obesity | ESPE2021

Assessment of Hyperphagia in Patients with Monogenic Obesity

Zorn Stefanie , von Schnurbein Julia , Schirmer Melanie , Kohlsdorf Katja , Brandt Stephanie , Wabitsch Martin ,

Introduction: Besides an excessive, early-childhood weight gain, hyperphagia is the key symptom in patients with monogenic obesity. However, the assessment of hyperphagia is still challenging. Here, we applied the hyperphagia questionnaire developed for patients with Prader-Willi-Syndrome (PWS) to assess the severity of hyperphagia in patients with monogenic obesity.Methods: Pediatric patients with biallelic pathogenic l...

hrp0097fc8.6 | Fat, metabolism and obesity 2 | ESPE2023

Liraglutide treatment in adolescents with extreme obesity - Effects on weight loss in the first 9 months under real-life conditions

Schirmer Melanie , Brandt Stephanie , Knupfer Magdalena , Zorn Stefanie , Weihrauch-Blüher Susann , Wabitsch Martin

Introduction: The Glucagon-like Peptide(GLP1)-analogue liraglutide is the first drug approved for the treatment of obesity in adolescents in Europe. While clinically relevant effects of liraglutide treatment in adolescents with obesity had been shown in a phase III study, there are no reports about the use under real-life conditions in these patients. Our aim was to report the effect of treatment with liraglutide on body weight loss in a cohort of adolescents ...

hrp0097p1-285 | Fetal, Neonatal Endocrinology and Metabolism | ESPE2023

Severe Neonatal Donohue Syndrome: Extreme Hyperinsulinemia, Progressive Hypertrophic Cardiomyopathy (HCM) and Failure to Thrive

Lämmer Constanze , Langer Johanna , de Potzolli Brigitte , Liebl Stefanie , M.K. Völkl Thomas

Introduction: Donohue syndrome (DS) is presenting as the most severe form of insulin resistance. Most of the patients are dying within the first two years of life. As potential treatment has been described the administration of rhIGF1 (Mecasermin) to stimulate the pathway of insulin-like action. An improved metabolic control was reported with continuous subcutaneous administration of rhIGF1 instead of twice daily injections [Plamper 2018].<p class="abstext...

hrp0095p1-473 | Fat, Metabolism and Obesity | ESPE2022

Prevalence and determinants of hyperuricemia in a Belgian multi-ethnic inner-city population of overweight/obese children and adolescents

Nauwynck Elise , Vanbesien Jesse , Staels Willem , Ryckx Sofie , Verheyden Stefanie , Rutteman Bart , Weets Ilse , De Schepper Jean , Gies Inge

Background/ Aims: Hyperuricemia (HU) is a frequent finding in childhood obesity, ranging between 12 and 40%, and associates to a variable extent with different components of the metabolic syndrome (MS). In this study, the effect of gender, (a Belgian native vs a non-Belgian native) descent and degree of general and central adiposity on serum uric acid (SUA) and the prevalence of HU was investigated in a multi-ethnic population of overweight/obese children and ...

hrp0086fc4.3 | Pathophysiology of Obesity | ESPE2016

Expression of Type 1 Insulin-like Growth Factor Receptor (IGF-1R) in Liver of Obese Children with Non-alcoholic Fatty Liver Disease (NAFLD)

Pampanini Valentina , De Stefanis Cristiano , Alisi Anna , Inzaghi Elena , Nobili Valerio , Cianfarani Stefano

Background: Type 1 insulin-like growth factor receptor (IGF-1R) is the product of a single-copy gene located on chromosome 15 and is ubiquitously expressed in humans. Increased hepatic IGF-1R gene expression is found in hepatocellular carcinoma and in chronic hepatitis C, making parenchymal and non-parenchymal cells more susceptible to the mitogenic effects of IGF-1.Objective and hypotheses: As we have previously demonstrated that IGF-1 and IGF-2 circula...

hrp0095p1-572 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2022

Long-term GnRHa use and bone health in transgender adolescents: can a mouse model inform clinical practice?

Ciancia Silvia , Dubois Vanessa , Claessens Frank , Craen Margarita , Doms Stefanie , El Kharraz Sara , Kim Nari , Klink Daniel , Vanderschueren Dirk , Cools Martine

Background: Transgender individuals increasingly present at gender services in childhood. Consequently, to suppress pubertal development, more adolescents are long-term exposed to gonadotropin-releasing hormone analogues (GnRHa), from onset of puberty until start of gender-affirming hormones (GAH), around 16 years. Prolonged GnRHa may compromise bone health more than shorter-term treatment. If earlier start of GAH, when psychologically indicated, may partially...

hrp0094p1-120 | Fat, Metabolism and Obesity B | ESPE2021

Monogenic obesity in children: focusing on SH2B1 deletion

Giannopoulou Eleni Z , Zorn Stefanie , Schirmer Melanie , Herrmann Gloria , Heger Sabine , Reinehr Thomas , Denzer Christian , Rabenstein Hannah , Schnurbein Julia von , Wabitsch Martin ,

Introduction: Monogenic obesity refers to a group of rare, early-onset forms of obesity and accounts for about 7% of patients with severe pediatric obesity. Recent reports demonstrate the emerging role of Src-homology-2 (SH2) B adaptor protein 1 (Sh2b1), an important component in the leptin-melanocortin pathway, as a key regulator of leptin and insulin signaling, with possible roles in the pathogenesis of obesity and diabetes. SH2B1 deletions are found to be a...